Home
Cancer types
Treatments
Support
News
Centres and oncologists
Search
Tuesday, November 10, 2026
Ogkologos.com
Home
Cancer types
Treatments
Support
News
Centres and oncologists
Home
Authors
Posts by Ogkologos
Ogkologos
4396 POSTS
0 COMMENTS
EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib
Ogkologos
-
July 31, 2025
0
FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk...
Ogkologos
-
July 31, 2025
0
HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours
Ogkologos
-
July 30, 2025
0
Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with...
Ogkologos
-
July 29, 2025
0
Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,...
Ogkologos
-
July 28, 2025
0
FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung...
Ogkologos
-
July 25, 2025
0
EMA Recommends Extension of Indications for Tislelizumab
Ogkologos
-
July 24, 2025
0
Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...
Ogkologos
-
July 23, 2025
0
Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in...
Ogkologos
-
July 22, 2025
0
ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...
Ogkologos
-
July 21, 2025
0
1
...
43
44
45
...
440
Page 44 of 440
MOST POPULAR
For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions
June 3, 2021
Bra Straps with Disappearing Message Remind Women to Check Their Breasts...
April 12, 2021
Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia
July 13, 2021
Stealing Strategies from Cancerous T Cells May Boost Immunotherapy
March 20, 2024
Load more
HOT NEWS
The new home for your research tools
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular...
How to Make the Most of Your Patient Portal During Cancer
Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily...
Ελληνικά
English (UK)
